top of page

TEAM

Sotirios.JPG

Sotirios Stergiopoulos, MD, MBEE, FACP

President & CEO, Founder

​Harvard Medical School, Bayer, Novartis, Celgene, CMO of Ipsen​

  • Chief Medical Officer, SVP and Head of Global Medical Affairs at Ipsen

  • Vice President and Head of Global Medical Affairs Oncology for Baxalta Inc and Shire & roles in medical affairs and clinical development at Bayer Pharmaceuticals, Novartis Pharmaceuticals and Celgene Corporation 

  • Trained in Internal Medicine and Cancer Genetics from NIH, Albert Einstein College of Medicine and Harvard Medical School

  • Masters of Biotechnology Enerprise and Entrepreneurship from Johns Hopkins University

unnamed.jpg

Edward Painter, MBA

Chairman & CIO, Founder

Research and Biotech focused capital markets with Goldman Sachs, Credit Suisse & UBS​​

  • MBA from University of Illinois at Urbana-Champaign

  • Former VP at UBS, Oppenheimer & Co., Credit Suisse, and Kidder Peabody

  • Former analyst at Goldman Sachs and Salomon Brothers

  • 30 years of experience in finance

  • Has worked extensively with biotech companies in financing and investment decisions

Screen Shot 2019-05-11 at 3.54.41 PM.png

Sridhar Vempati

Chief Strategy Officer & Executive VP of R&D, Founder

Harvard University Postdoc Leukemia Research, BD Ironwood and Rafael Pharma​

  • PhD in Human Biology from Ludwig-Maximilians University

  • MBA from Boston University

  • Postdoctoral research at Harvard University in leukemia and the target of AO-001

  • Authored several articles in oncology in leading publications

  • Biotechnology industry analyst experience at Jeffries LLC 

ChaeminLim_1_edited.jpg

Chaemin Lim, PhD

Chief Scientific Officer

Medicinal and Computational Chemist. Seoul National University, University of Pittsburgh, UPCDC ​

  • PhD in Synthetic and Medicinal Chemistry from the Seoul National University

  • Postdoctoral research in Chemistry from the University of Pittsburgh

  • Extensive research experience in synthetic organic chemistry and drug discovery covering multiple therapeutic areas

  • Co-authored 20 SCI papers and 9 patent applications as a co-inventor

  • Has contributed to drug discovery and development projects ranging from early development stages through to preclinical trials particularly using in silico drug design tools

Screen Shot 2025-06-02 at 2.17.01 PM.png

Robbin Frnka, B.S.

Vice President of Clinical Operations

Vice President of Clinical Operations 

  • Bachelor of Science, Oklahoma State University

  • Recipient of 2017 PRA President's Award

  • Co-Founder, Accelsobio

  • Executive Director of Clinical Development & Strategy, Proxima

bottom of page